A comparison of glycemic parameters and their relationship with C-peptide and Proinsulin levels during partial remission and non-remission periods in children with type 1 diabetes mellitus-a cross-sectional study

被引:3
作者
Yesiltepe-Mutlu, Gul [1 ,2 ]
Capaci, Merve [2 ]
Can, Ecem [1 ]
Gokce, Tugba [1 ]
Bayrakci, Gizem [1 ]
Muradoglu, Serra [1 ]
Incir, Said [3 ]
Cakir, Esra Papatya [4 ]
Hatun, Sukru [1 ,2 ]
机构
[1] Koc Univ Hosp, Dept Pediat Endocrinol & Diabet, TR-34010 Istanbul, Turkey
[2] Koc Univ, Sch Med, Istanbul, Turkey
[3] Koc Univ Hosp, Dept Biochem, Istanbul, Turkey
[4] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Pediat Endocrinol, Istanbul, Turkey
关键词
Type; 1; diabetes; Partial remission; C-peptide; Proinsulin;
D O I
10.1186/s12902-021-00681-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Currently, there is a lack of data relating to glycemic parameters and their relationship with C-peptide (CP) and proinsulin (PI) during the partial remission period (PRP) in type 1 diabetes mellitus (T1D). The aim of this study was to evaluate glycemic parameters in children with T1D who are in the PRP using intermittently scanned continuous glucose monitoring systems (isCGMS) and to investigate any relationships between CP and PI levels. Methods The study included 21 children who were in the PRP and 31 children who were not. A cross-sectional, non-randomized study was performed. Demographic, clinical data were collected and 2 week- isCGMS data were retrieved. Results The Serum CP showed a positive correlation with time-in-range in the PRP (p:0.03), however PI showed no correlations with glycemic parameters in both periods. The Serum CP and PI levels and the PI:CP ratio were significantly higher in the PRP group than in the non-PRP group. In the non-PRP group, the PI level was below 0.1 pmol/L (which is the detectable limit) in only 2 of the 17 cases as compared with none in the PRP group. Similarly, only 2 of the 17 children in the non-PRP group had CP levels of less than 0.2 nmol / L, although both had detectable PI levels. Overall time-in-range (3. 9-1.0 mmol/L) was significantly high in the PRP group. In contrast, the mean sensor glucose levels, time spent in hyperglycemia, and coefficient of variation levels (32.2vs 40.5%) were significantly lower in the PRP group. Conclusions Although the mean glucose and time in range during the PRP was better than that in the non-PRP group, the glycemic variability during this period was not as low as expected. While the CP levels showed an association with TIR during the PRP, there was no correlation between PI levels and glycemic parameters. Further studies are needed to determine if PI might prove to be a useful parameter in clinical follow-up.
引用
收藏
页数:9
相关论文
共 21 条
[1]  
Böber E, 2001, J PEDIATR ENDOCR MET, V14, P435
[2]   Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study [J].
Cengiz, Eda ;
Cheng, Peiyao ;
Ruedy, Katrina J. ;
Kollman, Craig ;
Tamborlane, William V. ;
Klingensmith, Georgeanna J. ;
Gal, Robin L. ;
Silverstein, Janet ;
Lee, Joyce ;
Redondo, Maria J. ;
Beck, Roy W. .
PEDIATRIC DIABETES, 2017, 18 (07) :566-573
[3]   The Type 1 diabetes 'honeymoon' period is five times longer in men who exercise: a case-control study [J].
Chetan, M. R. ;
Charlton, M. H. ;
Thompson, C. ;
Dias, R. P. ;
Andrews, R. C. ;
Narendran, P. .
DIABETIC MEDICINE, 2019, 36 (01) :127-128
[4]   Partial remission in type 1 diabetes and associated factors: Analysis based on the insulin dose-adjusted hemoglobin A1c in children and adolescents from a regional diabetes center, Auckland, New Zealand [J].
Chiavaroli, Valentina ;
Derraik, Jose G. B. ;
Jalaludin, Muhammad Y. ;
Albert, Benjamin B. ;
Ramkumar, Selvarajan ;
Cutfield, Wayne S. ;
Hofman, Paul L. ;
Jefferies, Craig A. .
PEDIATRIC DIABETES, 2019, 20 (07) :892-900
[5]   Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes [J].
Christensen, M. B. ;
Gaede, P. ;
Hommel, E. ;
Gotfredsen, A. ;
Norgaard, K. .
DIABETES & METABOLISM, 2020, 46 (01) :61-65
[6]   International Consensus on Use of Continuous Glucose Monitoring [J].
Danne, Thomas ;
Nimri, Revital ;
Battelino, Tadej ;
Bergenstal, Richard M. ;
Close, Kelly L. ;
DeVries, J. Hans ;
Garg, Satish ;
Heinemann, Lutz ;
Hirsch, Irl ;
Amiel, Stephanie A. ;
Beck, Roy ;
Bosi, Emanuele ;
Buckingham, Bruce ;
Cobelli, Claudio ;
Dassau, Eyal ;
Doyle, Francis J., III ;
Heller, Simon ;
Hovorka, Roman ;
Jia, Weiping ;
Jones, Tim ;
Kordonouri, Olga ;
Kovatchev, Boris ;
Kowalski, Aaron ;
Laffel, Lori ;
Maahs, David ;
Murphy, Helen R. ;
Norgaard, Kirsten ;
Parkin, Christopher G. ;
Renard, Eric ;
Saboo, Banshi ;
Scharf, Mauro ;
Tamborlane, William V. ;
Weinzimer, Stuart A. ;
Phillip, Moshe .
DIABETES CARE, 2017, 40 (12) :1631-1640
[7]  
Dean AG, OpenEpi: Open Source Epidemiologic Statistics for Public Health
[8]   Continuous Glucose Monitoring System in Free-Living Healthy Subjects: Results from a Pilot Study [J].
Derosa, Giuseppe ;
Salvadeo, Sibilla A. T. ;
Mereu, Roberto ;
D'Angelo, Angela ;
Ciccarelli, Leonardina ;
Piccinni, Mario N. ;
Ferrari, Ilaria ;
Gravina, Alessia ;
Maffioli, Pamela ;
Tinelli, Carmine .
DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 (03) :159-169
[9]  
DHAHIR FJ, 1992, CLIN CHEM, V38, P227
[10]   Glucagon secretion and signaling in the development of diabetes [J].
Gaisano, Herbert Y. ;
MacDonald, Patrick E. ;
Vranic, Mladen .
FRONTIERS IN PHYSIOLOGY, 2012, 3